Цимерная антигенная рецепторная терапия Т-клеток столь же эффективна и безопасна в пожилом возрасте ().≥70) и молодые пациенты с множественной миеломой: многоцентральный ретроспективный анализ.

Dear Editor,

The introduction of chimeric antigen receptor T-cell (CAR-T) therapies has significantly transformed the treatment landscape for patients with relapsed/refractory (r/r) multiple myeloma (MM). BCMA-directed CAR-T cell therapies, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have revolutionized the field by demonstrating remarkable efficacy in pivotal clinical trials [ 1 , 2 ]. With a median age at diagnosis of 69 years, older adults ( ≥ 70 years) represent a substantial proportion of the r/r MM population [ 3 ]. However, with a median age of 63 years and 61.5 years for KarMMa-3 and CARTITUDE-4, r/r MM patients aged ≥70 years are underrepresented in these trials [ 1 , 2 ]. This age group is more likely to have additional comorbidities and a higher frailty index, raising questions about the efficacy and safety of CAR-T therapies in this more vulnerable population [ 4 – 6 ].

In the present study, we sought to evaluate differences in clinical outcomes and toxicity profiles between elderly patients aged 70 years and older and their younger counterparts. By identifying age-related differences, we aim to provide insights that could inform patient selection, risk stratification, and supportive care strategies for optimizing the use of CAR-T therapies in clinical practice.

This retrospective study enrolled 148 r/r MM patients treated with idecabtagene vicleucel (ide-cel) ( n = 140/148) and ciltacabtagene autoleucel (cilta-cel) ( n = 8/148) between March 2022 and September 2024 in seven German and one Swiss hospitals. Clinical data were retrospectively extracted from the medical records and electronic patient files and informed consent was obtained. The study was approved by the Ethics Committee of the University Hospital Münster (approval number 2024-068-f-S) and was performed in accordance with the Declaration of Helsinki. The details on definitions and statistical analysis are presented in Supplementary Information. Age 70 years was used as the prespecified cutoff for age-stratified analyses based on exploratory spline modeling (Supplementary Fig. 1 ). Based on this, 96 patients (64.9%) were <70 years and 52 patients (35.1%) were ≥70 years of age at the time of CAR-T infusion. The participating centers contributed between 8 and 40 patients each, with the proportion of patients aged ≥70 years ranging from 20% to 53% across all seven centers.

Baseline characteristics by age group ( < 70 vs. ≥70 years) are summarized in Table 1 . Elderly patients had significantly higher comorbidity (CCI ≥ 4: 71.2% vs. 28.1%; p < 0.001) and frailty (IMWG simplified frailty: 84.0% vs. 55.6%) compared with younger patients. In contrast, prior treatment exposure, disease risk stratification using the MyCARe score [ 7 ], number of prior therapy lines, and response status at CAR-T infusion were comparable between groups. Table 1 Baseline characteristics of all patients. Variable Total cohort ( N = 148) < 70 years ( N = 96) ≥ 70 years ( N = 52) P -value Median age at CAR-T infusion in years [Min, Max] 65.0 [37.0, 82.6] 61.0 [37.0, 69.3] 73.0 [70.0, 82.6] <0.001 Age at CAR-T infusion in categories <0.001 <60 years 44 (29.7%) 44 (45.8%) 0 (0%) 60–69 years 52 (35.1%) 52 (54.2%) 0 (0%) ≥ 70 years 52 (35.1%) 0 (0%) 52 (100%) <75 years 36 (69.2%) ≥75 years 16 (30.8%) Female 56 (37.8%) 40 (41.7%) 16 (30.8%) 0.217 ECOG 0.544 0–1 119 (90.8%) 77 (89.5%) 42 (93.3%) >1 12 (9.2%) 9 (10.5%) 3 (6.7%) Missing 17 10 7 Charlson Comorbidity Index (CCI) <0.001 0–1 14 (9.5%) 13 (13.5%) 1 (1.9%) 2–3 70 (47.3%) 56 (58.3%) 14 (26.9%) ≥4 64 (43.2%) 27 (28.1%) 37 (71.2%) Simplified frailty score <0.001 Frail 92 (65.7%) 50 (55.6%) 42 (84.0%) Non-frail 48 (34.3%) 40 (44.4%) 8 (16.0%) Missing 8 6 2 Myeloma Type 0.209 IgG 85 (57.8%) 51 (53.7%) 34 (65.4%) IgA 28 (19.0%) 23 (24.2%) 5 (9.6%) IgM 3 (2.0%) 1 (1.1%) 2 (3.8%) Kappa 14 (9.5%) 8 (8.4%) 6 (11.5%) Lambda 14 (9.5%) 10 (10.5%) 4 (7.7%) asecretory 3 (2.0%) 2 (2.1%) 1 (1.9%) Missing 1 1 0 R-ISS Stage at Diagnosis 0.119 I 30 (24.0%) 19 (23.8%) 11 (24.4%) II 47 (37.6%) 35 (43.8%) 12 (26.7%) III 48 (38.4%) 26 (32.5%) 22 (48.9%) Missing 23 16 7 High-Risk Cytogenetics (17p deletion, t(4;14), t(14;16), t(14;20)) 64 (48.1%) 47 (52.8%) 17 (38.6%) 0.143 CAR-T Product 0.452 Ide-cel 140 (94.6%) 92 (95.8%) 48 (92.3%) Cilta-cel 8 (5.4%) 4 (4.2%) 4 (7.7%) Plasma cell leukemia 1 (0.7%) 1 (1.0%) 0 (0%) 1 Extramedullary disease 56 (37.8%) 40 (41.7%) 16 (30.8%) 0.217 MyCARe score 0.293 low (0-1) 40 (27.0%) 24 (25.0%) 16 (30.8%) intermediate (2–3) 88 (59.5%) 56 (58.3%) 32 (61.5%) high (4) 20 (13.5%) 16 (16.7%) 4 (7.7%) Prior treatment lines ( Median, Min, Max) 5.00 [3.00, 15.0] 5.00 [3.00, 15.0] 5.00 [3.00, 12.0] 0.316 Lenalidomide refractory 123 (83.1%) 80 (83.3%) 43 (82.7%) 1 Triple refractory 136 (91.9%) 89 (92.7%) 47 (90.4%) 0.754 Penta refractory 80 (54.1%) 48 (50.0%) 32 (61.5%) 0.227 Previous BCMA-directed Therapy 21 (14.3%) 14 (14.7%) 7 (13.5%) 1 Prior HDCT/autoSCT 134 (90.5%) 90 (93.8%) 44 (84.6%) 0.0828 Prior alloSCT 9 (6.1%) 7 (7.3%) 2 (3.8%) 0.494 Response status at CAR-T infusion 0.367 CR/VGPR/PR 52 (35.9%) 31 (33.0%) 21 (41.2%) nonPR 93 (64.1%) 63 (67.0%) 30 (58.8%) Missing 3 2 1 Holding/Bridging therapy prior to CAR-T 0.729 Holding therapy 36 (24.3%) 21 (21.9%) 15 (28.8%) Bridging therapy Conventional anti-CD38/PI/IMiD regimens 83 (56.1%) 54 (56.3%) 29 (55.8%) Chemotherapy-based 21 (14.2%) 15 (15.6%) 6 (11.5%) Bispecific antibodies 8 (5.4%) 6 (6.3%) 2 (3.8%) Number of applied bridging therapies 1 103 (70.1%) 68 (71.6%) 35 (67.3%) 0.526 2 8 (5.4%) 6 (6.3%) 2 (3.8%) 3 2 (1.4%) 2 (2.1%) 0 (0%) Missing 1 1 0 Median time apheresis-CAR -T (days) 58.0 [2.00, 252] 58.5 [43.0, 200] 58.0 [2.00, 252] 0.94 Median time diagnosis-CAR-T (years) 7.00 [0, 26.2] 6.75 [0, 26.2] 7.90 [0, 19.5] 0.94 Median follow-up of survivors in months post-CAR-T 8.65 [0.400, 26.5] 9.25 [0.400, 24.4] 7.20 [0.400, 26.5] 0.202 CAR-T chimeric antigen receptor T-cell, ECOG Eastern Cooperative Oncology Group performance status, CCI Charlson Comorbidity Index, R-ISS, Revised International Staging System, BCMA B-cell maturation antigen, Ide-cel idecabtagene vicleucel, Cilta-cel ciltacabtagene autoleucel, HDCT high-dose chemotherapy, autoSCT autologous stem cell transplantation, alloSCT allogeneic stem cell transplantation, PI proteasome inhibitor, IMiD immunomodulatory drugs, CR complete response, VGPR very good partial response, PR partial response, nonPR less than partial response. Bold values just highlight a statistical significance.

The use and type of holding or bridging therapy prior to CAR-T were comparable between both groups (Table 1 ). Overall, 24.3% of patients received holding therapy, while the remainder required bridging therapy. Among bridged patients, conventional anti-CD38/PI/IMiD regimens were most frequently used, accounting for 56.1% of all cases. Chemotherapy-based regimens were administered in 14.2%, and bispecific antibodies in 5.4% as bridging therapy. Most patients received one line of bridging therapy (70.1%); 5.4% and 1.4% received two and three distinct bridging regimens, respectively.

Outcomes after CAR-T cell therapy are shown in Supplementary Table 1 and Fig. 1 . Fig. 1 Age-stratified efficacy and safety outcomes. Age-stratified outcomes comparing patients <70 years (red) and ≥70 years (blue). A Overall survival (OS) and ( B ) progression-free survival (PFS) were compared using the log-rank test. C Relapse incidence (RI) and ( D ) non-relapse mortality (NRM) was compared using Gray’s test. Numbers at risk are shown below each plot. E Best response before and after CAR-T therapy by age group; p -values indicate within-group paired comparisons of CR rates before versus after CAR-T. F Distribution of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) grades according to age.

With a median follow-up of 8.7 months among survivors (range: 0.4–27 months), the cumulative incidence of relapse at 12 months was comparable between age groups - 41.4% (95% CI: 22.3–59.5%) in patients aged ≥70 years versus 48.3% (95% CI: 35.6–59.9%) in those <70 years (Fig. 1A ). In contrast, the cumulative incidence of non-relapse mortality (NRM) was numerically higher in the older cohort, reaching 17.1% (95% CI: 7.1–30.8%) compared to 6.7% (95% CI: 2.3–14.1%) in younger patients (Fig. 1B ) ( p = 0.10). The estimated 12-month PFS rates were 43.5% (95% CI: 32.7–57.8%) and 47.8% (95% CI: 32.8–69.7%) for patients <70 and ≥70 years, respectively, while the corresponding 12-month OS rates were 74.4% (95% CI: 64.8–85.6%) and 68.4% (95% CI: 54.3–86.1%) (both p > 0.05) (Fig. 1C, D ). The overall response rate, indicated by achieving a CR or (VG)PR as the best response, was 78.7% ( < 70 years) and 94.1% ( ≥ 70 years) for both age groups ( p = 0.002), respectively. In both age groups, response depth significantly improved post-infusion, with a higher CR-rate observed among older patients (58.8% vs. 42.6%) (Fig. 1E ).

Figure 1F and Supplementary Table 1 summarize treatment-related toxicities, hematologic recovery, and early outcomes after CAR-T therapy stratified by age group. Severe cytokine release syndrome (CRS; grade >2) occurred in 7.5% of patients overall (7.4% vs. 7.7% in those; p = 1.0). Grade >2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 3.2% of younger patients and in none of the older cohort. Hematologic recovery and immunoglobulin nadirs were comparable between age groups.

After propensity score matching ( n = 47 per group), baseline characteristics were largely balanced, although extramedullary disease remained more frequent in younger patients (Supplementary Table 2 ). In the matched cohort, age-stratified OS and RI/NRM patterns remained comparable (Supplementary Fig. 2 ). Univariable and multivariable competing-risks regression identified factors associated with relapse incidence and NRM (Supplementary Fig. 3A ; Supplementary Table 3 ). For RI, extramedullary disease, intermediate/high MyCARe (both p < 0.05), and a higher number of prior therapy lines were associated with increased risk in univariable analyses; in multivariable analysis, high-risk MyCARe [ 4 ] remained associated with RI (HR = 3.30, p = 0.012). For NRM, prior HDCT/ASCT was associated with reduced risk (HR = 0.19, p = 0.004), whereas age group, simplified frailty, and prior therapy lines were not significant after adjustment. In multivariable Cox models for OS and PFS (Supplementary Fig. 3B ; Supplementary Table 4 ), high-risk MyCARe [ 4 ] was associated with inferior PFS (HR = 3.63, p = 0.004) and OS (HR = 3.46, p = 0.041). Frailty was associated with reduced OS (HR = 2.45, p = 0.039), while prior HDCT/ASCT was favorable (HR = 0.29, p = 0.009). A higher number of prior therapy lines was associated with decreased PFS (HR = 1.11 per line, p = 0.030); other covariates, including age group, were not significant after adjustment.

Beyond efficacy, our analyses highlight the persistent risk of non-relapse mortality, predominantly driven by infections in patients treated with CAR-T. Our data is consistent with the fatal infections reported in large meta-analyses underscoring the importance of structured follow-up and preventive strategies, particularly in elderly and comorbid patients. Immune monitoring, including serial immunoglobulin assessment and markers of immune may help identify patients at increased risk for severe infections. Preventive measures should include immunoglobulin substitution when indicated, antibacterial and antiviral prophylaxis, and vaccination strategies to reduce infectious complications. Despite being a multicenter study, the sample size, particularly for the ≥70 years subgroup, was limited, which may reduce the power to detect differences in less frequent outcomes such as NRM. The possible bias such analyses like presented here is patient selection. Younger patients may represent a more unfavorable group due to more aggressive disease characteristics, while elderly patients are evaluated more thoroughly in terms of eligibility to CAR-T cell therapy. Additionally, limited follow-up time limits the ability to assess long-term outcomes and durability of response. The retrospective design and the predominance of ide-cel patients also introduce potential bias in patient selection and data completeness.

Limited data exist on cilta-cel outcomes in elderly and frail patients. Recent conference abstracts by Velayati et al. found no age-related differences in efficacy or toxicity among 64 patients aged ≥75 versus 128 younger patients receiving cilta-cel [ 8 ], while Mian et al. reported that frailty ( ≥ 2 points on simplified frailty index) was not associated with response or CRS grade ≥2 risk in 183 frail versus 358 non-frail cilta-cel recipients [ 9 ], though overall survival was inferior. These findings are consistent with our predominantly ide-cel cohort results. As such, larger cilta-cel-specific studies are warranted given its increasing use and distinct toxicity profile. Importantly, a strength of our analysis is that most elderly patients (84%) were frail, supporting the feasibility of CAR-T in a clinically vulnerable real-world population.

However, despite a significantly higher prevalence of frailty and comorbidities in patients aged ≥70 years, we observed comparable clinical outcomes after BCMA-directed CAR-T therapy in older and younger patients, with similar overall response rates exceeding 80% and no significant differences in PFS or OS. Second, treatment-related toxicities, including high-grade CRS, ICANS, infections, and hematologic recovery, were not increased in the elderly cohort, supporting the feasibility of CAR-T therapy in this population. Notably, comparable findings have been observed in other real-world studies analyzing the efficacy and safety of CD19- or BCMA-directed CAR-T cell therapy in patients with aggressive B-cell lymphoma [ 10 – 13 ] or multiple myeloma [ 8 , 14 ] (Supplementary Table 5A and 5B ).

Third, after propensity score matching for relevant clinical variables, survival outcomes remained comparable between age groups, reinforcing that age alone should not be a barrier to CAR-T eligibility. Finally, multivariable analyses highlighted that risk factors such as high MyCARe score, comorbidity burden represented by the simplified frailty scoring (which incorporates the CCI) were more strongly associated with adverse outcomes, including relapse incidence, NRM, and OS, than an age cutoff of 70 years. These findings should encourage clinicians to offer BCMA targeted CAR-T cell therapies to elderly patients with a clear indication and support a more individualized approach to CAR-T selection. Furthermore, they underscore the importance of integrating frailty and disease biology into treatment decision-making.

Supplementary information

Supplemental material

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Thomas Pabst, Evgenii Shumilov.

Supplementary information

The online version contains supplementary material available at 10.1038/s41408-026-01531-w.

Author contributions

PB, TP, and ES conceived the study. PB and ES performed data analysis and wrote the manuscript. TP and ES jointly supervised the work. All authors contributed data, critically revised the manuscript, and approved the final version.

Data availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to data protection restrictions.

Competing interests

GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria not related to this study from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. MM received honoraria from AbbVie, AstraZeneca, Gilead and Lilly and congress/travel support from AbbVie, Gilead, Stemline therapeutics, Incyte, Sobi and Johnson & Johnson. RWK received honoraria from BMS, Gilead, Hexal, Roche, and Sobi. AB received honoraria from GSK, AstraZeneca, Menarini StemLine, Johnson and Johnson, Pfizer Oncopeptides, BMS; Advisory Board: GSK, AstraZeneca, Menarini StemLine, Johnson and Johnson, Pfizer Oncopeptides; and has received travel support from Pfizer, AstraZeneca, Johnson and Johnson, BMS. MS has served as a consultant for Pfizer, MSD, Bristol-Myers Squibb (BMS), Incyte, Takeda, Astellas, Autolus, Sanofi and Amgen; as a speaker for Pfizer, Medac, MSD, Astellas, Jazz Pharmaceuticals, Amgen, Novartis, Gilead, Celgene, BMS, AbbVie, and Incyte; has received research funding from Pfizer; and has received travel support from Medac, Sanofi and Pfizer. FHH is a consultant for BMS/Celgene, AOP, Novartis, CTI, Janssen, AbbVie, GSK, Merck, CTI, Kartos, Telios, Silence Therapeutics, Prelude Therapeutics, Geron and Sumitomo and received research funding from: Novartis, BMS/Celgene and CTI. ES received honoraria not related to this manuscript from Amgen, BMS, Sanofi, Oncopeptides, Gilead, Incyte, Lilly, Roche, Abbvie and Takeda.

References

1. Rodriguez-Otero P Ailawadhi S Arnulf B Patel K Cavo M Nooka AK Ide-cel or standard regimens in relapsed and refractory multiple myeloma N Engl J Med 2023 388 1002 14 10.1056/NEJMoa2213614 36762851 Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002–14. 36762851 10.1056/NEJMoa2213614

2. San-Miguel J Dhakal B Yong K Spencer A Anguille S Mateos MV Cilta-cel or standard care in lenalidomide-refractory multiple myeloma N Engl J Med 2023 389 335 47 10.1056/NEJMoa2303379 37272512 San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335–47. 37272512 10.1056/NEJMoa2303379

3. Siegel RL Giaquinto AN Jemal A Cancer statistics, 2024 CA Cancer J Clin 2024 74 12 49 38230766 10.3322/caac.21820 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. 38230766 10.3322/caac.21820

4. Engelhardt M Domm AS Dold SM Ihorst G Reinhardt H Zober A A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients Haematologica 2017 102 910 21 10.3324/haematol.2016.162693 28154088 PMC5477610 Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910–21. 28154088 10.3324/haematol.2016.162693 PMC5477610

5. Facon T Dimopoulos MA Meuleman N Belch A Mohty M Chen WM A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Leukemia 2020 34 224 33 10.1038/s41375-019-0539-0 31427722 PMC7214253 Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224–33. 31427722 10.1038/s41375-019-0539-0 PMC7214253

6. Palumbo A Bringhen S Mateos MV Larocca A Facon T Kumar SK Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Blood 2015 125 2068 74 10.1182/blood-2014-12-615187 25628469 PMC4375104 Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–74. 25628469 10.1182/blood-2014-12-615187 PMC4375104

7. Gagelmann N Dima D Merz M Hashmi H Ahmed N Tovar N Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma J Clin Oncol 2024 42 1665 75 10.1200/JCO.23.02232 38358946 PMC11095856 Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:1665–75. 38358946 10.1200/JCO.23.02232 PMC11095856

8. Velayati A Jensen A Dima D Rana M Peres L Shune L Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM) Blood 2025 146 6375 10.1182/blood-2025-6375 Velayati A, Jensen A, Dima D, Rana M, Peres L, Shune L, et al. Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM). Blood. 2025;146:6375.

9. Mian H Faisal MS Chen T Brazauskas R Oloyede T Ahmed N Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis Blood 2025 146 133 10.1182/blood-2025-133 Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, et al. Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis. Blood. 2025;146:133.40638200

10. Chihara D Liao L Tkacz J Franco A Lewing B Kilgore KM Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma Blood 2023 142 1047 55 10.1182/blood.2023020197 37339585 Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, et al. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 2023;142:1047–55. 37339585 10.1182/blood.2023020197

11. Dreger P Holtick U Subklewe M von Tresckow B Ayuk F Wagner E Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience Bone Marrow Transpl 2023 58 229 32 10.1038/s41409-022-01867-4 PMC9902271 36418916 Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, et al. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience. Bone Marrow Transpl. 2023;58:229–32. 10.1038/s41409-022-01867-4 PMC9902271 36418916

12. Berning P Shumilov E Maulhardt M Boyadzhiev H Kerkhoff A Call S Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study Hemasphere 2024 8 e54 10.1002/hem3.54 38510993 PMC10953542 Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, et al. Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study. Hemasphere. 2024;8:e54. 38510993 10.1002/hem3.54 PMC10953542

13. Ram R Grisariu S Shargian-Alon L Amit O Bar-On Y Stepensky P Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study Haematologica 2022 107 1111 8 10.3324/haematol.2021.278288 34233446 PMC9052918 Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 2022;107:1111–8. 34233446 10.3324/haematol.2021.278288 PMC9052918

14. Akhtar OS Oloyede T Brazauskas R Afrough A Hashmi H Sidana S Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study Blood Adv 2025 9 1587 92 10.1182/bloodadvances.2024014970 39786391 PMC11986210 Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025;9:1587–92. 39786391 10.1182/bloodadvances.2024014970 PMC11986210